These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27488222)

  • 41. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies.
    Kawamoto Y; Kobayashi Y; Suzuki Y; Inoue H; Tomimoto H; Akiguchi I; Budka H; Martins LM; Downward J; Takahashi R
    J Neuropathol Exp Neurol; 2008 Oct; 67(10):984-93. PubMed ID: 18800009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain.
    Zhang S; Dauer K; Strohäker T; Tatenhorst L; Caldi Gomes L; Mayer S; Jung BC; Kim WS; Lee SJ; Becker S; Liesche-Starnecker F; Zweckstetter M; Lingor P
    Brain Pathol; 2023 Sep; 33(5):e13196. PubMed ID: 37485772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation on the Molecular Interactions Stabilizing the Structure of α-synuclein Fibril: An In silico Study.
    Sanjeev A; Mattaparthi VSK
    Cent Nerv Syst Agents Med Chem; 2017; 17(3):209-218. PubMed ID: 28460628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
    Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
    J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical localization of spatacsin in α-synucleinopathies.
    Kuru S; Yoshida M; Tatsumi S; Mimuro M
    Neuropathology; 2014 Apr; 34(2):135-9. PubMed ID: 24112408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential.
    Ferreira N; Gram H; Sorrentino ZA; Gregersen E; Schmidt SI; Reimer L; Betzer C; Perez-Gozalbo C; Beltoja M; Nagaraj M; Wang J; Nowak JS; Dong M; Willén K; Cholak E; Bjerregaard-Andersen K; Mendez N; Rabadia P; Shahnawaz M; Soto C; Otzen DE; Akbey Ü; Meyer M; Giasson BI; Romero-Ramos M; Jensen PH
    Acta Neuropathol; 2021 Jul; 142(1):87-115. PubMed ID: 33978813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson's disease.
    Lau HHC; Martinez-Valbuena I; So RWL; Mehra S; Silver NRG; Mao A; Stuart E; Schmitt-Ulms C; Hyman BT; Ingelsson M; Kovacs GG; Watts JC
    Acta Neuropathol Commun; 2023 May; 11(1):72. PubMed ID: 37138318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology.
    Teil M; Dovero S; Bourdenx M; Arotcarena ML; Camus S; Porras G; Thiolat ML; Trigo-Damas I; Perier C; Estrada C; Garcia-Carrillo N; Morari M; Meissner WG; Herrero MT; Vila M; Obeso JA; Bezard E; Dehay B
    Brain; 2022 Apr; 145(3):1001-1017. PubMed ID: 35285474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.
    Donadio V; Incensi A; El-Agnaf O; Rizzo G; Vaikath N; Del Sorbo F; Scaglione C; Capellari S; Elia A; Stanzani Maserati M; Pantieri R; Liguori R
    Sci Rep; 2018 Sep; 8(1):14246. PubMed ID: 30250046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy.
    Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG
    Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. α-Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases.
    So RWL; Watts JC
    J Mol Biol; 2023 Jun; 435(12):168011. PubMed ID: 36792008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo.
    Dutta D; Jana M; Majumder M; Mondal S; Roy A; Pahan K
    Nat Commun; 2021 Sep; 12(1):5382. PubMed ID: 34508096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies.
    Piao YS; Mori F; Hayashi S; Tanji K; Yoshimoto M; Kakita A; Wakabayashi K; Takahashi H
    Acta Neuropathol; 2003 Apr; 105(4):403-9. PubMed ID: 12624794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infectious Agents as Potential Drivers of α-Synucleinopathies.
    Linard M; Ravier A; Mougué L; Grgurina I; Boutillier AL; Foubert-Samier A; Blanc F; Helmer C
    Mov Disord; 2022 Mar; 37(3):464-477. PubMed ID: 35040520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies.
    Peng C; Gathagan RJ; Covell DJ; Medellin C; Stieber A; Robinson JL; Zhang B; Pitkin RM; Olufemi MF; Luk KC; Trojanowski JQ; Lee VM
    Nature; 2018 May; 557(7706):558-563. PubMed ID: 29743672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Truncation or proteolysis of α-synuclein in Parkinsonism.
    Suthar SK; Lee SY
    Ageing Res Rev; 2023 Sep; 90():101978. PubMed ID: 37286088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
    Martinez-Valbuena I; Amat-Villegas I; Valenti-Azcarate R; Carmona-Abellan MDM; Marcilla I; Tuñon MT; Luquin MR
    Acta Neuropathol; 2018 Jun; 135(6):877-886. PubMed ID: 29536165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The heart of PD: Lewy body diseases as neurocardiologic disorders.
    Goldstein DS; Sharabi Y
    Brain Res; 2019 Jan; 1702():74-84. PubMed ID: 29030055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.